Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2022)
Spero Therapeutics' (SPRO) quarterly Income from Non-Controlling Interests came in at $6000.0 in Q2 2022, up 500.0% YoY from $1000.0 in Q2 2021, and up 250.0% on a QoQ basis from -$4000.0 in Q1 2022.
Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2022) Analysis & Trends
Spero Therapeutics (SPRO) has 7 years of Income from Non-Controlling Interests data on file, last reported at $6000.0 in Q2 2022.
- Quarterly Income from Non-Controlling Interests rose 500.0% year-over-year to $6000.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $6000.0 (up 300.0% YoY) and the FY2022 annual result came in at $2000.0, down 60.0% from the prior year.
- Income from Non-Controlling Interests grew to $6000.0 in Q2 2022, from -$4000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $34000.0 in Q2 2020 to a low of -$35000.0 in Q1 2020.
- A 5-year average of $0.0 and a median of -$500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 580.0% in 2020, down 300.0% in 2020.
- Tracing SPRO's Income from Non-Controlling Interests over 5 years: stood at -$5000.0 in 2018, then soared by 60.0% to -$2000.0 in 2019, then slumped by 300.0% to -$8000.0 in 2020, then soared by 112.5% to $1000.0 in 2021, then soared by 500.0% to $6000.0 in 2022.
- The last three Income from Non-Controlling Interests figures came in at $6000.0 (Q2 2022), -$4000.0 (Q1 2022), and $1000.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Dec 31, 2020 | -8,000.00 |
| Sep 30, 2020 | -14,000.00 |
| Jun 30, 2020 | 34,000.00 |
| Mar 31, 2020 | -35,000.00 |
| Dec 31, 2019 | -2,000.00 |
| Sep 30, 2019 | 12,000.00 |
| Jun 30, 2019 | 5,000.00 |
| Mar 31, 2019 | 29,000.00 |
| Dec 31, 2018 | -5,000.00 |
| Sep 30, 2018 | -8,000.00 |
| Jun 30, 2018 | 14,000.00 |
| Mar 31, 2018 | -29,000.00 |
| Dec 31, 2017 | -6,000.00 |
| Sep 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -594,000.00 |
| Mar 31, 2017 | -535,000.00 |